Bilateral subconjunctival hemorrhage secondary to abciximab use

case report

Autores

  • Selim Kul Department of Cardiology, Trabzon Ahi Evren Cardiovascular and Thoracic Surgery Research and Application Center, Saglik Bilimleri University
  • Muhammet Raşit Sayın Department of Cardiology, Trabzon Ahi Evren Cardiovascular and Thoracic Surgery Research and Application Center, Saglik Bilimleri University

Palavras-chave:

Conjunctivitis, acute hemorrhagic, Abciximab [supplementary concept], Coronary disease

Resumo

CONTEXT: There are no reports on cases of subconjunctival hemorrhage due to use of glycoprotein IIb/IIIa inhibitors. In this report, we present the case of a patient with bilateral subconjunctival hemorrhage after receiving abciximab. CASE REPORT: A 40-year-old male patient underwent coronary angiography after acute anterior myo-cardial infarction and a coronary stent was placed. Abciximab was added to the therapy because of stent thrombosis. Bilateral subconjunctival hemorrhage was observed after the administration of the abciximab treatment. We treated our patient by stopping abciximab and administering artificial tears. CONCLUSİON: For the first time in the literature, we presented the case of a patient with bilateral subcon-junctival hemorrhage after receiving abciximab, which was managed conservatively.

Downloads

Não há dados estatísticos.

Biografia do Autor

Selim Kul, Department of Cardiology, Trabzon Ahi Evren Cardiovascular and Thoracic Surgery Research and Application Center, Saglik Bilimleri University

MD. Cardiology Specialist, Saglik Bilimleri University, Department of Cardiology, Trabzon Ahi Evren Cardiovascular and Thoracic Surgery Research and Application Center, Saglik Bilimleri University, Trabzon, Turkey.

Muhammet Raşit Sayın, Department of Cardiology, Trabzon Ahi Evren Cardiovascular and Thoracic Surgery Research and Application Center, Saglik Bilimleri University

MD. Associate Professor, Saglik Bilimleri University, Department of Cardiology, Trabzon Ahi Evren Cardiovascular and Thoracic Surgery Research and Application Center, Saglik Bilimleri University, Trabzon, Turkey.

Referências

Ibbotson T, McGavin JK, Goa KL. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63.

Authors/Task Force members, Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541-619.

EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330(14):956-61.

Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-52.

Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy. 2008;28(11):1354-73.

Nguyen TM, Phelan MP, Werdich XQ, Rychwalski PJ, Huff CM. Subconjunctival hemorrhage in a patient on dabigatran (Pradaxa). Am J Emerg Med. 2013;31(2):455.e3-5.

Black RA, Bensinger RE. Bilateral subconjunctival hemorrhage after acetylsalicylic acid overdose. Ann Ophthalmol. 1982;14(11):1024-5.

Downloads

Publicado

2019-04-04

Como Citar

1.
Kul S, Sayın MR. Bilateral subconjunctival hemorrhage secondary to abciximab use: case report. Sao Paulo Med J [Internet]. 4º de abril de 2019 [citado 14º de março de 2025];137(2):209-11. Disponível em: https://periodicosapm.emnuvens.com.br/spmj/article/view/832

Edição

v. 137 n. 2 (2019)

Seção

Relato de Caso

Licença

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.